Nimbus Therapeutics has raised $105 million to put its allosteric TYK2 inhibitor through a clutch of phase 2 clinical trials. The multifront midphase program is designed to determine whether the drug ...
Fifty years ago, weather forecasting began a seismic shift, one which brought meteorology and weather forecasting to a level that would be impossible without this technology. The Nimbus program ...
Sotyktu (deucravacitinib), the tyrosine kinase 2 (TYK2) inhibitor for psoriasis from Bristol Myers Squibb Co., is “a good first-in-class” drug, said Nimbus Therapeutics LLC CEO Jeb Keiper, but his ...
FOSTER CITY, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) and Nimbus Therapeutics, LLC today announced that the companies have signed a definitive agreement under ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotech that integrates computational chemistry and other advanced technologies to design breakthrough medicines and transform drug ...
Nimbus Therapeutics said yesterday it has won a $200 million milestone payment from Gilead Sciences based on progress in its clinical development of the allosteric acetyl-CoA carboxylase (ACC) ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through its powerful computational discovery engine, today announced initiation of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results